Colorectal cancer (CRC) is the third most common cancer globally and the second leading cause of cancer-related mortality worldwide.¹ Outcomes remain particularly poor in patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation, which is associated with highly aggressive tumor biology, poor survival, and reduced responsiveness to current therapeutic strategies.^1,2 Despite this high unmet need, there were previously no biomarker-driven therapies specifically indicated for untreated BRAF V600E-mutant mCRC.¹ New findings from cohort 3 of the phase 3 BREAKWATER trial show significantly improved objective response rates (ORR) in encorafenib + cetuximab (EC) combined with a folinic acid, fluorouracil, and irinotecan (FOLFIRI) backbone cohort, supporting its potential as a new standard of care in this high-risk population.³

BRAF mutations are estimated to occur in approximately 8%-12% of patients with mCRC and are associated with poor prognosis.⁴ Among these, BRAF V600E is the most common variant, with mortality risk reported to be more than double compared with patients without known mutations.^4,5 Historically, this subgroup has shown limited benefit from standard chemotherapy, and overall survival outcomes remain poor despite the addition of anti-vascular endothelial growth factor (VEGF) therapy, underscoring the need for more effective targeted strategies.^2,4 Against this backdrop, encorafenib, a selective oral BRAF inhibitor, in combination with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab, is used for patients with BRAF V600E-mutant mCRC whose disease has progressed after first- or second-line therapy.^1,2

BREAKWATER is a pivotal phase 3, randomized, open-label, multicenter study evaluating EC, either alone or in combination with chemotherapy (mFOLFOX6), as the first-line treatment in patients with previously untreated BRAF V600E-mutant mCRC.⁴ While earlier trial findings have already supported encorafenib-based combinations as a promising targeted strategy, cohort 3 was designed to determine whether pairing encorafenib and cetuximab with an alternative chemotherapy backbone (FOLFIRI) could further expand treatment flexibility and optimize clinical outcomes.^3,6 Eligible patients in cohort 3 had untreated BRAF V600E-mutant mCRC, measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.³ Patients were randomized 1:1 to receive EC + FOLFIRI or control (FOLFIRI ± bevacizumab).³

In BREAKWATER cohort 3 analysis, EC + FOLFIRI significantly improved ORR vs. standard-of-care FOLFIRI ± bevacizumab in first-line BRAF V600E-mutant mCRC, achieving an ORR of 64.4% compared with 39.2% (odds ratio [OR]=2.76; 95% CI: 1.42-5.35; p=0.001), demonstrating a clinically meaningful and statistically significant improvement in tumor response.³ Durability outcomes further supported the benefit of the investigational combination.³ Although the median duration of response was not estimable in either arm at the time of analysis, 57.4% of responding patients in the EC + FOLFIRI arm maintained responses lasting at least six months, compared with 34.5% in the control group.³

Overall survival data remain immature; however, early descriptive findings were encouraging.³ EC + FOLFIRI reduced the risk of death by 51% vs. the control group (HR=0.49; 95% CI: 0.24-1.03), with a median follow-up of approximately 10 months in both study arms.³ While confirmatory survival conclusions cannot yet be drawn, the observed trend suggests the possibility of survival benefit with longer follow-up.³ The safety profile of EC + FOLFIRI was consistent with the established safety profiles of the individual agents, with no new safety signals reported.³ Serious treatment-emergent adverse events occurred in 39.4% of patients receiving EC + FOLFIRI vs. 36.8% in the control arm.³ Importantly, the addition of encorafenib + cetuximab did not substantially increase treatment discontinuation, with FOLFIRI discontinuation rates of 9.9% in the EC + FOLFIRI arm vs. 8.8% in the control arm.³

In conclusion, the BREAKWATER cohort 3 findings demonstrate a clinically meaningful and statistically significantly higher and durable response rates vs. standard FOLFIRI-based therapy in BRAF V600E-mutant mCRC.³ These results support the feasibility of encorafenib + cetuximab to be paired with an additional chemotherapy backbone, reinforcing its potential as a precision-driven frontline option for this aggressive disease subtype.³